Innovation | Novartis

Media Release
Nov 20, 2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Media Release
Nov 09, 2023
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Media Release
Oct 31, 2023
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Media Release
Oct 26, 2023
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
Media Release
Oct 24, 2023
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
Media Release
Oct 24, 2023
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
Media Release
Oct 24, 2023
Novartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023
Media Release
Aug 09, 2023
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Media Release
Jul 18, 2023
Novartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²
Media Release
Jul 18, 2023
Novartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²
Media Release
Jul 18, 2023
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²
Media Release
Jun 30, 2023
Novartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis